CELLDEX THERAPEUTICS INC NEW's ticker is and the CUSIP is 15117B902. A total of 4 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,227 | +465.4% | 44,600 | +596.9% | 0.00% | – |
| Q2 2023 | $217 | -80.9% | 6,400 | -79.7% | 0.00% | -100.0% |
| Q1 2023 | $1,136 | +433.3% | 31,600 | +558.3% | 0.00% | – |
| Q4 2022 | $213 | -99.9% | 4,800 | -32.4% | 0.00% | – |
| Q3 2022 | $199,000 | -98.0% | 7,100 | -98.1% | 0.00% | -100.0% |
| Q2 2022 | $9,959,000 | +206.9% | 369,400 | +287.6% | 0.01% | +266.7% |
| Q1 2022 | $3,245,000 | +69.0% | 95,300 | +91.8% | 0.00% | +50.0% |
| Q4 2021 | $1,920,000 | +4263.6% | 49,700 | +3723.1% | 0.00% | – |
| Q3 2021 | $44,000 | +2.3% | 1,300 | 0.0% | 0.00% | – |
| Q2 2021 | $43,000 | -47.6% | 1,300 | +3150.0% | 0.00% | – |
| Q1 2021 | $82,000 | -77.5% | 40 | -80.8% | 0.00% | – |
| Q4 2020 | $364,000 | -31.7% | 208 | -42.2% | 0.00% | -100.0% |
| Q3 2020 | $533,000 | -0.2% | 360 | -12.4% | 0.00% | 0.0% |
| Q2 2020 | $534,000 | +341.3% | 411 | -43.7% | 0.00% | – |
| Q1 2020 | $121,000 | +611.8% | 730 | +824.1% | 0.00% | – |
| Q4 2019 | $17,000 | -34.6% | 79 | -37.3% | 0.00% | – |
| Q3 2019 | $26,000 | +62.5% | 126 | +103.2% | 0.00% | – |
| Q2 2019 | $16,000 | +433.3% | 62 | +785.7% | 0.00% | – |
| Q1 2019 | $3,000 | – | 7 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PURA VIDA INVESTMENTS, LLC | 196,600 | $8,762,462 | 0.45% |
| GROUP ONE TRADING, L.P. | 42,200 | $1,880,854 | 0.00% |
| SIMPLEX TRADING, LLC | 4,800 | $213 | 0.00% |
| JANE STREET GROUP, LLC | 14,800 | $659,636 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |